FDA expands approval for cystic fibrosis drug

While the FDA originally approved Kalydeco to treat 10 rare gene mutations associated with the disease, the drug now can be used to treat 33 mutations.

Cystic fibrosis patients take Kalydeco — in a tablet or oral granule form — twice a day for improved lung function, among other benefits.

Medtronic to acquire pain management devicemaker for $650M

Medtronic said it plans to acquire SPR Therapeutics, a medical technology company focused on peripheral nerve stimulation therapies for chronic…

FDA creates new infection diagnostic device category

The FDA has created a new category of infection diagnostic devices designed to detect microorganism nucleic acids and antimicrobial resistance…

FDA alerts hospitals to anesthesia machine issue

The FDA has issued an early alert for certain Draeger anesthesia workstations tied to a manufacturing issue that could cause…

More articles on supply chain:

Next Up in Supply Chain

Medtronic to acquire pain management devicemaker for $650M

FDA creates new infection diagnostic device category

FDA alerts hospitals to anesthesia machine issue

More articles on supply chain:

Next Up in Supply Chain

Join the 500,000+ healthcare executives who start their day with Becker’s